Amisulpride as the antipsychotic of choice in severe psychotic disorder with comorbid impaired glucose tolerance
| Autor: | Sumaila Asif, Jigyansa Ipsita Pattnaik, Syed Shahruq Ahmed, Jayprakash Russell Ravan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Industrial Psychiatry Journal, Vol 33, Iss 1, Pp 168-171 (2024) |
| Druh dokumentu: | article |
| ISSN: | 0972-6748 0976-2795 |
| DOI: | 10.4103/ipj.ipj_133_23 |
| Popis: | Antipsychotics are the mainstay treatment for the majority of severe mental illnesses. Such patients are also more prone to develop medical comorbidities, which complicate the treatment decisions. It is estimated that up to 40% of individuals with schizophrenia have impaired glucose tolerance (IGT) or diabetes, which can be attributed to a combination of genetic, lifestyle, and medication-related factors. Some widely used antipsychotic medications like olanzapine, risperidone, and clozapine have been associated with an increased risk of weight gain, insulin resistance, and other metabolic abnormalities, which can worsen IGT and increase the risk of developing diabetes. Among second-generation antipsychotics (SGAs), amisulpride, aripirazole, and ziprasidone have a fairly low potency to cause obesity and hyperglycemia. In this context, clinicians must balance the benefits and risks of different antipsychotic medications and consider the individual's specific needs and preferences. Here, we shall discuss three cases, to ascertain how the use of amisulpride helped in glycemic control, and also reflect on probable etiologies leading to deranged glucose levels. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|